Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

NCT01023776 | Completed Phase 4 Results

• 1 other identifier: URMC 09-006
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.

Conditions

Influenza

Keywords

Swine Flu; H1N1

Outcome Measures

Primary Outcomes (1)

• Number of Participants Who Shed Virus

  number of participants who shed virus above the limit of detection at any timepoint after vaccine. The limit of detection is 0.5 tissue culture infectious doses per mL of nasal wash.

  28 days post vaccine 1 and 28 days vaccine 2

Secondary Outcomes (1)

• Mean Difference Between Cycle Time and Detection Threshold

  day 10 post vaccine 1

Study Arms (1)

live monovalent H1N1 vaccine

OTHER

A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart

Biological: A/California/07/09 live monovalent H1N1 vaccine

Interventions

A/California/07/09 live monovalent H1N1 vaccine BIOLOGICAL

0.1mL per nares intranasally, second identical dose given 28 days after first vaccine

Also known as: Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

live monovalent H1N1 vaccine

Eligibility Criteria

• Age: 18 Years - 32 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Aged 18-32 years, inclusive
• No history of Novel H1N1 virus or vaccine
• Female not able to bear children or not pregnant and agrees to practice effective birth control
• Female negative pregnancy test
• Good Health
• Ability to understand and comply with protocol
• Provided Informed Consent

You may not qualify if:

• Previous history of vaccination against novel H1N1 or laboratory documented H1N1 infection
• History of egg allergy or is allergic to other components of the vaccine
• A women who is pregnant or breastfeeding or intends to get pregnant during the study period between enrollment and 30 days following vaccination
• Subject is immunosuppressed as the result of underlying illness or treatment with immunosuppressive or cytotoxic drugs or use of chemotherapy or radiation therapy in the preceding 36 months
• Subject has active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy. "active is defined as treatment within the past 5 years
• Long term (greater than 2 weeks) use of oral or parental steroids, or high- dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids allowed)
• Received immunoglobulin or another blood product within 3 months prior to enrollment in this study
• Subject has received an inactivated vaccine within 2 weeks or a live vaccine within 4 weeks prior to enrollment in this study or plans to receive another vaccine within the next 28 days (or 56 days for the vaccine naive recipients)
• Subject has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. Those conditions include chronic conditions recognized as risk factors for influenza complications or as contraindicated for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment
• Subject has an acute illness or an oral temperature greater then 99.9 degrees F(37.7 C)within 3 days prior to enrollment or vaccination. Subject who has acute illness that was treated, symptoms resolved are eligible to enroll as long as treatment is complete and symptoms resolved \> 3 dyas prior to enrollment.
• Subject is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month prior to enrollment in this study, or intends to donate blood during this period.
• Subject has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
• Subject has a history of alcohol or drug abuse in the 5 years prior to enrollment.
• Subject has known human immunodeficiency virus, hepatitis B, or hepatitis C infection.
• Subject has a previous history of Guillain-Barre syndrome within 6 weeks of receipt of influenza vaccine

Sponsors & Collaborators

• University of Rochester: lead

Study Sites (1)

Vaccine Research Unit Room 3-5000

Rochester, New York, 14642, United States

Location

MeSH Terms

Conditions

Influenza, Human; Orthomyxoviridae Infections

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Results Point of Contact

• Title: John Treanor< M.D.
• Organization: University of Rochester

john_treanor@urmc.rochester.edu

585-275-5871

Study Officials

• John J. Treanor, M.D.

  University of Rochester

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: M.D.

Study Record Dates

• First Submitted: December 1, 2009
• First Posted: December 2, 2009
• Study Start: November 1, 2009
• Primary Completion: April 1, 2010
• Study Completion: July 1, 2010
• Last Updated: December 23, 2015
• Results First Posted: December 23, 2015

Record last verified: 2015-11

Locations

US (1)